Portfolio Holdings Detail for ISIN IE00BDZVHG35
Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /var/www/liquidata/show_ticker_holding_ETFs.php on line 77
Stock Name / Fund iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer Blackrock

ETF Ticker BTEE(USD) LSE
ETF Ticker BTEE.L(GBP) LSE

Holdings detail for APLS

Stock Name	Apellis Pharmaceuticals Inc
Ticker	APLS(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US03753U1060
LEI	254900HS0ZFRXXSB9D42

Show aggregate APLS holdings

News associated with APLS

Short Interest in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Grows By 34.0%: Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) was the recipient of a large growth in short interest in the month of July. As of July 31st, there was short interest totaling 22,090,000 shares, agrowthof34.0% from the July 15th total of 16,490,000 shares. Based on an average daily volume of 2,450,000 shares, the days-to-cover ratio […] - 2025-08-22 05:26:48
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock Holdings Lessened by Deutsche Bank AG: Deutsche Bank AG trimmed its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 0.1% in the first quarter, Holdings Channel.com reports. The firm owned 1,776,576 shares of the company’s stock after selling 1,801 shares during the quarter. Deutsche Bank AG’s holdings in Apellis Pharmaceuticals were worth $38,854,000 as of its most recent SEC […] - 2025-08-13 04:52:53
Mackenzie Financial Corp Grows Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS): Mackenzie Financial Corp increased its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 14.2% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 41,533 shares of the company’s stock after purchasing an additional 5,175 shares during the […] - 2025-08-06 05:57:02
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Acquired by Assetmark Inc.: Assetmark Inc. boosted its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 3,938.7% in the first quarter, HoldingsChannel.com reports. The firm owned 1,252 shares of the company’s stock after acquiring an additional 1,221 shares during the period. Assetmark Inc.’s holdings in Apellis Pharmaceuticals were worth $27,000 as of its most recent filing with […] - 2025-08-06 04:52:49
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Raised to $37.00 at JPMorgan Chase & Co.: Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) had its price objective lifted by analysts at JPMorgan Chase & Co. from $35.00 to $37.00 in a research report issued on Monday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective indicates a potential upside of 52.89% from the […] - 2025-08-06 03:02:54
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Raised to $19.00: Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its price target raised by Royal Bank Of Canada from $17.00 to $19.00 in a research report sent to investors on Friday,Benzinga reports. Royal Bank Of Canada currently has a sector perform rating on the stock. A number of other equities research analysts have also recently commented on […] - 2025-08-04 04:26:49
Citigroup Increases Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $46.00: Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its price target lifted by Citigroup from $41.00 to $46.00 in a report published on Tuesday,Benzinga reports. Citigroup currently has a buy rating on the stock. A number of other brokerages have also weighed in on APLS. Morgan Stanley raised their price objective on shares of Apellis Pharmaceuticals […] - 2025-07-30 04:46:46
Apellis Pharma Secures FDA Approval For EMPAVELI To Treat Rare Kidney Disorders: (RTTNews) - Apellis Pharmaceuticals Inc. (APLS) announced that the U.S. Food and Drug Administration has approved EMPAVELI (pegcetacoplan) as the first treatment for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients 1 - 2025-07-29 01:03:26
Arizona State Retirement System Lowers Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS): Arizona State Retirement System cut its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 7.9% in the 1st quarter, HoldingsChannel.com reports. The fund owned 19,539 shares of the company’s stock after selling 1,665 shares during the period. Arizona State Retirement System’s holdings in Apellis Pharmaceuticals were worth $427,000 as of its most recent […] - 2025-07-23 06:58:58
Cerity Partners LLC Boosts Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS): Cerity Partners LLC increased its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 16.7% during the first quarter, Holdings Channel reports. The firm owned 54,444 shares of the company’s stock after acquiring an additional 7,777 shares during the quarter. Cerity Partners LLC’s holdings in Apellis Pharmaceuticals were worth $1,191,000 at the end of […] - 2025-07-23 06:58:56
Diversified Trust Co Takes $282,000 Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS): Diversified Trust Co purchased a new position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 12,878 shares of the company’s stock, valued at approximately $282,000. Other hedge funds and other institutional […] - 2025-07-02 05:18:55
Analysts Anticipate IYH To Hit $66: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-06-23 08:47:36
Analysts Anticipate IYH To Hit $66: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-06-23 08:47:26
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Acquired by Assenagon Asset Management S.A.: Assenagon Asset Management S.A. lifted its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 147.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 74,325 shares of the company’s stock after buying an additional 44,332 shares during the quarter. Assenagon Asset Management S.A.’s […] - 2025-06-18 04:42:57
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stake Lifted by Merit Financial Group LLC: Merit Financial Group LLC increased its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 324.4% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,762 shares of the company’s stock after buying an additional 25,806 shares during the quarter. Merit […] - 2025-06-09 05:46:43
Wealth Enhancement Advisory Services LLC Purchases 19,641 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS): Wealth Enhancement Advisory Services LLC increased its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 140.8% during the 4th quarter, Holdings Channel reports. The firm owned 33,594 shares of the company’s stock after purchasing an additional 19,641 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Apellis Pharmaceuticals were […] - 2025-06-09 04:48:45
Apellis Pharmaceuticals (NASDAQ:APLS) Trading Up 7.7% on Analyst Upgrade: Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) shot up 7.7% during mid-day trading on Monday after Wells Fargo & Company raised their price target on the stock from $26.00 to $29.00. Wells Fargo & Company currently has an equal weight rating on the stock. Apellis Pharmaceuticals traded as high as $18.50 and […] - 2025-06-04 02:01:06
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Raised to $29.00: Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its price target increased by Wells Fargo & Company from $26.00 to $29.00 in a research report released on Monday,Benzinga reports. They currently have an equal weight rating on the stock. APLS has been the subject of a number of other reports. Wedbush cut their price objective on […] - 2025-06-03 02:52:45
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Position Raised by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC: UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 11.4% during the 4th quarter, Holdings Channel.com reports. The firm owned 212,887 shares of the company’s stock after buying an additional 21,822 shares during the quarter. UBS AM a […] - 2025-06-02 05:32:58
14,564 Shares in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Purchased by Vident Advisory LLC: Vident Advisory LLC purchased a new stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 14,564 shares of the company’s stock, valued at approximately $465,000. Several other institutional investors and hedge funds have also recently […] - 2025-05-28 05:31:01
Captrust Financial Advisors Buys Shares of 12,629 Apellis Pharmaceuticals, Inc. (NASDAQ:APLS): Captrust Financial Advisors purchased a new position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) during the fourth quarter, Holdings Channel.com reports. The fund purchased 12,629 shares of the company’s stock, valued at approximately $403,000. Several other hedge funds have also made changes to their positions in APLS. Teacher Retirement System of Texas […] - 2025-05-20 04:47:07
Apellis Pharmaceuticals (NASDAQ:APLS) Reaches New 52-Week Low on Analyst Downgrade: Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) reached a new 52-week low on Wednesday after Mizuho lowered their price target on the stock from $30.00 to $20.00. Mizuho currently has a neutral rating on the stock. Apellis Pharmaceuticals traded as low as $16.61 and last traded at $16.69, with a volume of […] - 2025-05-16 03:00:51
Ameriprise Financial Inc. Boosts Stock Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS): Ameriprise Financial Inc. boosted its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 2.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 882,801 shares of the company’s stock after purchasing an additional 22,507 shares during the period. […] - 2025-05-14 07:10:45
Bank of America Corp DE Has $53.62 Million Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS): Bank of America Corp DE increased its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 72.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,680,213 shares of the company’s stock after purchasing an additional 705,209 shares during the period. Bank of […] - 2025-05-14 06:12:50
The Manufacturers Life Insurance Company Decreases Stock Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS): The Manufacturers Life Insurance Company cut its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 13.6% in the fourth quarter, Holdings Channel.com reports. The fund owned 52,897 shares of the company’s stock after selling 8,324 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Apellis Pharmaceuticals were worth $1,688,000 as of […] - 2025-05-12 06:10:47
Apellis Pharmaceuticals (NASDAQ:APLS) Cut to Outperform at Raymond James: Raymond James cut shares of Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) from a strong-buy rating to an outperform rating in a research note released on Friday, MarketBeat reports. They currently have $52.00 price target on the stock, down from their previous price target of $75.00. Other equities research analysts have also issued reports about the […] - 2025-05-12 05:12:48
Robert W. Baird Cuts Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $47.00: Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its price objective trimmed by Robert W. Baird from $55.00 to $47.00 in a report released on Thursday,Benzinga reports. The firm currently has an outperform rating on the stock. A number of other research analysts have also weighed in on APLS. HC Wainwright reiterated a “buy” rating and […] - 2025-05-11 05:40:50
Apellis Pharmaceuticals (NASDAQ:APLS) Lowered to Neutral Rating by Bank of America: Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) was downgraded by investment analysts at Bank of America from a “buy” rating to a “neutral” rating in a research note issued to investors on Friday, Marketbeat Ratings reports. They currently have a $23.00 target price on the stock, down from their previous target price of $41.00. Bank […] - 2025-05-11 05:40:50
Apellis Pharmaceuticals (NASDAQ:APLS) Hits New 52-Week Low Following Weak Earnings: Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) hit a new 52-week low during trading on Wednesday following a weaker than expected earnings announcement. The stock traded as low as $16.65 and last traded at $18.78, with a volume of 490307 shares. The stock had previously closed at $19.12. The company reported ($0.74) […] - 2025-05-08 03:08:52
Legal & General Group Plc Sells 10,879 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS): Legal & General Group Plc decreased its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 11.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 86,771 shares of the company’s stock after selling 10,879 shares during the quarter. Legal & General Group Plc […] - 2025-04-24 05:18:56

iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) APLS holdings

Date	Number of APLS Shares Held	Base Market Value of APLS Shares	Local Market Value of APLS Shares	Change in APLS Shares Held	Change in APLS Base Value	Current Price per APLS Share Held	Previous Price per APLS Share Held
2025-11-11 (Tuesday)	82,430	USD 1,608,209	USD 1,608,209	0	USD 42,039	USD 19.51	USD 19
2025-11-10 (Monday)	82,430	USD 1,566,170	USD 1,566,170	211	USD -17,368	USD 19	USD 19.26
2025-11-07 (Friday)	82,219	USD 1,583,538	USD 1,583,538	0	USD -36,998	USD 19.26	USD 19.71
2025-11-06 (Thursday)	82,219	USD 1,620,536	USD 1,620,536	211	USD -15,524	USD 19.71	USD 19.95
2025-11-05 (Wednesday)	82,008	USD 1,636,060	USD 1,636,060	0	USD -42,644	USD 19.95	USD 20.47
2025-11-04 (Tuesday)	82,008	USD 1,678,704	USD 1,678,704	212	USD -13,655	USD 20.47	USD 20.69
2025-11-03 (Monday)	81,796	USD 1,692,359	USD 1,692,359	0	USD -63,801	USD 20.69	USD 21.47
2025-10-31 (Friday)	81,796	USD 1,756,160	USD 1,756,160	1,060	USD 82,503	USD 21.47	USD 20.73
2025-10-30 (Thursday)	80,736	USD 1,673,657	USD 1,673,657	0	USD -752,460	USD 20.73	USD 30.05
2025-10-29 (Wednesday)	80,736	USD 2,426,117	USD 2,426,117	424	USD 12,741	USD 30.05	USD 30.05
2025-10-28 (Tuesday)	80,312	USD 2,413,376	USD 2,413,376	0	USD 21,685	USD 30.05	USD 29.78
2025-10-27 (Monday)	80,312	USD 2,391,691	USD 2,391,691	0	USD 129,302	USD 29.78	USD 28.17

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of APLS by Blackrock for IE00BDZVHG35

Show aggregate share trades of APLS

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-11-10 BUY 211 19.555 18.950 19.011 USD 4,011 23.71
2025-11-06 BUY 211 20.120 19.530 19.589 USD 4,133 23.76
2025-11-04 BUY 212 20.650 19.440 19.561 USD 4,147 23.80
2025-10-31 BUY 1,060 21.800 19.260 19.514 USD 20,685 23.83
2025-10-29 BUY 424 30.050 30.435 30.396 USD 12,888 23.81
2025-10-22 SELL -844 28.140 28.720 28.662 USD -24,191 23.66 Loss of -4,222 on sale
2025-10-20 BUY 422 27.070 27.800 27.727 USD 11,701 23.61
2025-10-17 BUY 1,059 24.520 24.845 24.812 USD 26,276 23.61
2025-10-15 BUY 1,688 25.220 25.390 25.373 USD 42,830 23.60
2025-10-03 BUY 1,456 23.800 23.940 23.926 USD 34,836 23.60
2025-10-02 BUY 208 23.110 23.395 23.367 USD 4,860 23.60
2025-09-30 BUY 416 22.630 22.990 22.954 USD 9,549 23.61
2025-09-26 BUY 416 22.370 22.400 22.397 USD 9,317 23.62
2025-09-25 BUY 416 22.220 22.790 22.733 USD 9,457 23.63
2025-09-18 BUY 219 23.380 23.790 23.749 USD 5,201 23.63
2025-09-17 BUY 660 23.130 24.140 24.039 USD 15,866 23.64
2025-07-17 SELL -438 20.040 20.605 20.548 USD -9,000 23.71 Profit of 1,387 on sale
2025-07-16 BUY 1,392 19.750 19.925 19.907 USD 27,711 23.74
2025-07-11 SELL -1,728 19.440 19.545 19.535 USD -33,756 23.82 Profit of 7,411 on sale
2025-07-02 BUY 11,880 17.820 18.600 18.522 USD 220,041 23.96
2025-06-25 BUY 432 18.390 18.610 18.588 USD 8,030 24.13
2025-06-20 BUY 1,819 17.690 18.085 18.045 USD 32,825 24.26
2025-06-11 BUY 420 19.270 19.900 19.837 USD 8,332 24.57
2025-06-10 BUY 420 19.580 19.960 19.922 USD 8,367 24.61
2025-06-04 SELL -210 18.510 19.290 19.212 USD -4,035 24.78 Profit of 1,170 on sale
2025-04-23 BUY 210 17.490 18.355 18.268 USD 3,836 26.88
2025-04-10 SELL -1,672 18.790 19.240 19.195 USD -32,094 27.73 Profit of 14,266 on sale
2025-04-08 SELL -209 18.700 20.480 20.302 USD -4,243 27.92 Profit of 1,593 on sale
2025-04-07 SELL -209 19.800 19.900 19.890 USD -4,157 28.02 Profit of 1,699 on sale
2025-04-04 SELL -1,045 19.970 23.100 22.787 USD -23,812 28.11 Profit of 5,566 on sale
2025-04-01 BUY 1,905 22.680 23.770 23.661 USD 45,074 28.24
2025-03-31 SELL -618 21.870 23.995 23.783 USD -14,698 28.32 Profit of 2,803 on sale
2025-03-21 BUY 3,228 24.140 24.575 24.532 USD 79,188 28.65
2025-03-14 SELL -3,136 24.660 24.810 24.795 USD -77,757 28.94 Profit of 12,986 on sale
2025-03-07 SELL -390 25.040 25.490 25.445 USD -9,924 29.23 Profit of 1,476 on sale
2025-03-04 SELL -196 25.050 25.560 25.509 USD -5,000 29.41 Profit of 765 on sale
2025-02-25 BUY 390 26.900 27.680 27.602 USD 10,765 29.73
2025-02-19 SELL -195 28.390 28.460 28.453 USD -5,548 29.87 Profit of 275 on sale
2025-02-13 BUY 585 27.460 28.680 28.558 USD 16,706 30.05
2025-02-12 BUY 195 28.510 28.540 28.537 USD 5,565 30.08
2025-02-11 BUY 780 28.530 29.140 29.079 USD 22,682 30.11
2024-12-30 SELL -5,277 31.900 32.500 32.440 USD -171,186 30.17 Loss of -11,984 on sale
2024-11-18 SELL -3,120 26.180 26.655 26.608 USD -83,015 27.93 Profit of 4,123 on sale
2024-11-08 SELL -208 29.980 30.140 30.124 USD -6,266 27.69 Loss of -507 on sale
2024-10-21 SELL -209 26.880 28.000 27.888 USD -5,829 0.00 Loss of -5,829 on sale
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-11-10	BUY	211	19.555	18.950	19.011	USD 4,011	23.71
2025-11-06	BUY	211	20.120	19.530	19.589	USD 4,133	23.76
2025-11-04	BUY	212	20.650	19.440	19.561	USD 4,147	23.80
2025-10-31	BUY	1,060	21.800	19.260	19.514	USD 20,685	23.83
2025-10-29	BUY	424	30.050	30.435	30.396	USD 12,888	23.81
2025-10-22	SELL	-844	28.140	28.720	28.662	USD -24,191	23.66 Loss of -4,222 on sale
2025-10-20	BUY	422	27.070	27.800	27.727	USD 11,701	23.61
2025-10-17	BUY	1,059	24.520	24.845	24.812	USD 26,276	23.61
2025-10-15	BUY	1,688	25.220	25.390	25.373	USD 42,830	23.60
2025-10-03	BUY	1,456	23.800	23.940	23.926	USD 34,836	23.60
2025-10-02	BUY	208	23.110	23.395	23.367	USD 4,860	23.60
2025-09-30	BUY	416	22.630	22.990	22.954	USD 9,549	23.61
2025-09-26	BUY	416	22.370	22.400	22.397	USD 9,317	23.62
2025-09-25	BUY	416	22.220	22.790	22.733	USD 9,457	23.63
2025-09-18	BUY	219	23.380	23.790	23.749	USD 5,201	23.63
2025-09-17	BUY	660	23.130	24.140	24.039	USD 15,866	23.64
2025-07-17	SELL	-438	20.040	20.605	20.548	USD -9,000	23.71 Profit of 1,387 on sale
2025-07-16	BUY	1,392	19.750	19.925	19.907	USD 27,711	23.74
2025-07-11	SELL	-1,728	19.440	19.545	19.535	USD -33,756	23.82 Profit of 7,411 on sale
2025-07-02	BUY	11,880	17.820	18.600	18.522	USD 220,041	23.96
2025-06-25	BUY	432	18.390	18.610	18.588	USD 8,030	24.13
2025-06-20	BUY	1,819	17.690	18.085	18.045	USD 32,825	24.26
2025-06-11	BUY	420	19.270	19.900	19.837	USD 8,332	24.57
2025-06-10	BUY	420	19.580	19.960	19.922	USD 8,367	24.61
2025-06-04	SELL	-210	18.510	19.290	19.212	USD -4,035	24.78 Profit of 1,170 on sale
2025-04-23	BUY	210	17.490	18.355	18.268	USD 3,836	26.88
2025-04-10	SELL	-1,672	18.790	19.240	19.195	USD -32,094	27.73 Profit of 14,266 on sale
2025-04-08	SELL	-209	18.700	20.480	20.302	USD -4,243	27.92 Profit of 1,593 on sale
2025-04-07	SELL	-209	19.800	19.900	19.890	USD -4,157	28.02 Profit of 1,699 on sale
2025-04-04	SELL	-1,045	19.970	23.100	22.787	USD -23,812	28.11 Profit of 5,566 on sale
2025-04-01	BUY	1,905	22.680	23.770	23.661	USD 45,074	28.24
2025-03-31	SELL	-618	21.870	23.995	23.783	USD -14,698	28.32 Profit of 2,803 on sale
2025-03-21	BUY	3,228	24.140	24.575	24.532	USD 79,188	28.65
2025-03-14	SELL	-3,136	24.660	24.810	24.795	USD -77,757	28.94 Profit of 12,986 on sale
2025-03-07	SELL	-390	25.040	25.490	25.445	USD -9,924	29.23 Profit of 1,476 on sale
2025-03-04	SELL	-196	25.050	25.560	25.509	USD -5,000	29.41 Profit of 765 on sale
2025-02-25	BUY	390	26.900	27.680	27.602	USD 10,765	29.73
2025-02-19	SELL	-195	28.390	28.460	28.453	USD -5,548	29.87 Profit of 275 on sale
2025-02-13	BUY	585	27.460	28.680	28.558	USD 16,706	30.05
2025-02-12	BUY	195	28.510	28.540	28.537	USD 5,565	30.08
2025-02-11	BUY	780	28.530	29.140	29.079	USD 22,682	30.11
2024-12-30	SELL	-5,277	31.900	32.500	32.440	USD -171,186	30.17 Loss of -11,984 on sale
2024-11-18	SELL	-3,120	26.180	26.655	26.608	USD -83,015	27.93 Profit of 4,123 on sale
2024-11-08	SELL	-208	29.980	30.140	30.124	USD -6,266	27.69 Loss of -507 on sale
2024-10-21	SELL	-209	26.880	28.000	27.888	USD -5,829	0.00 Loss of -5,829 on sale

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of APLS

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	365,951	217	673,015	54.4%
2025-09-18	285,735	50	519,270	55.0%
2025-09-17	295,048	30,671	719,091	41.0%
2025-09-16	268,069	0	669,559	40.0%
2025-09-15	472,442	0	1,211,606	39.0%
2025-09-12	243,658	537	571,702	42.6%
2025-09-11	324,798	0	885,655	36.7%
2025-09-10	267,030	0	588,974	45.3%
2025-09-09	262,802	0	694,326	37.8%
2025-09-08	280,153	15	1,256,019	22.3%
2025-09-05	470,716	0	1,440,543	32.7%
2025-09-04	448,960	0	843,699	53.2%
2025-09-03	386,359	0	1,028,029	37.6%
2025-09-02	508,044	27	892,486	56.9%
2025-08-29	256,747	0	579,909	44.3%
2025-08-28	233,432	0	526,732	44.3%
2025-08-27	176,278	10	583,646	30.2%
2025-08-26	202,812	100	448,389	45.2%
2025-08-25	214,541	15	390,398	55.0%
2025-08-22	583,700	0	847,502	68.9%
2025-08-21	312,614	188	498,544	62.7%
2025-08-20	429,472	0	902,247	47.6%
2025-08-19	289,360	330	683,248	42.4%
2025-08-18	333,780	200	651,337	51.2%
2025-08-15	807,427	50	1,538,259	52.5%
2025-08-14	935,273	1,951	1,791,869	52.2%
2025-08-13	1,007,850	1,073	1,415,032	71.2%
2025-08-12	517,598	19	695,025	74.5%
2025-08-11	211,272	0	424,917	49.7%
2025-08-08	328,063	0	529,055	62.0%
2025-08-07	515,705	0	871,950	59.1%
2025-08-06	419,041	12	817,335	51.3%
2025-08-05	541,450	0	1,137,551	47.6%
2025-08-04	608,183	0	1,365,407	44.5%
2025-08-01	936,366	4,190	1,730,769	54.1%
2025-07-31	1,335,944	1,752	2,982,326	44.8%
2025-07-30	950,484	5,220	1,345,399	70.6%
2025-07-29	1,105,200	7,848	2,166,605	51.0%
2025-07-28	716,459	0	1,011,538	70.8%
2025-07-25	286,282	52	505,613	56.6%
2025-07-24	396,864	1,354	663,345	59.8%
2025-07-23	282,566	0	473,690	59.7%
2025-07-22	490,254	500	749,215	65.4%
2025-07-21	259,333	0	398,582	65.1%
2025-07-18	289,701	0	501,305	57.8%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Stock Name / Fund	iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer	Blackrock
ETF Ticker	BTEE(USD) LSE
ETF Ticker	BTEE.L(GBP) LSE